Molecular Biosystems completes Oralex Phase I trials
This article was originally published in Clinica
Molecular Biosystems hopes to begin Phase II trials of its orally-administered abdominal ultrasound imaging agent, Oralex, this summer following completion of Phase I trials. The agent was more effective than water, the standard agent for this procedure, in displacing gas in the stomach and slowing the gastric emptying process, says MBI. The results are awaiting FDA review.